Biolight Life Sciences Stock Current Asset
| BOLT Stock | ILS 428.00 10.30 2.35% |
BioLight Life Sciences fundamentals help investors to digest information that contributes to BioLight Life's financial success or failures. It also enables traders to predict the movement of BioLight Stock. The fundamental analysis module provides a way to measure BioLight Life's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioLight Life stock.
BioLight |
BioLight Life Sciences Company Current Asset Analysis
BioLight Life's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current BioLight Life Current Asset | 45 M |
Most of BioLight Life's fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioLight Life Sciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
In accordance with the recently published financial statements, BioLight Life Sciences has a Current Asset of 45 M. This is 97.91% lower than that of the Life Sciences Tools & Services sector and 95.76% lower than that of the Health Care industry. The current asset for all Israel stocks is 99.52% higher than that of the company.
BioLight Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioLight Life's direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioLight Life could also be used in its relative valuation, which is a method of valuing BioLight Life by comparing valuation metrics of similar companies.BioLight Life is currently under evaluation in current asset category among its peers.
BioLight Fundamentals
| Return On Equity | -0.0911 | |||
| Return On Asset | -0.0925 | |||
| Current Valuation | 13.59 M | |||
| Shares Outstanding | 4.56 M | |||
| Shares Owned By Insiders | 56.36 % | |||
| Shares Owned By Institutions | 9.12 % | |||
| Price To Earning | 82.18 X | |||
| Price To Book | 0.61 X | |||
| Price To Sales | 4,937 X | |||
| Revenue | 3 K | |||
| Gross Profit | 3 K | |||
| EBITDA | (1.36 M) | |||
| Net Income | 382 K | |||
| Cash And Equivalents | 39.85 M | |||
| Cash Per Share | 8.77 X | |||
| Current Ratio | 15.24 X | |||
| Book Value Per Share | 13.87 X | |||
| Cash Flow From Operations | (10.03 M) | |||
| Earnings Per Share | 0.08 X | |||
| Target Price | 12.0 | |||
| Beta | 0.53 | |||
| Market Capitalization | 31.98 M | |||
| Total Asset | 64.17 M | |||
| Retained Earnings | (218 M) | |||
| Working Capital | 39 M | |||
| Current Asset | 45 M | |||
| Current Liabilities | 6 M | |||
| Z Score | -4.2 | |||
| Net Asset | 64.17 M |
About BioLight Life Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioLight Life Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioLight Life using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioLight Life Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in BioLight Stock
BioLight Life financial ratios help investors to determine whether BioLight Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioLight with respect to the benefits of owning BioLight Life security.